Table 1 Potential small molecules for treating bladder cancer cells by targeting the PTTG1 transcriptional regulatory network
Perturbagen | Cell line | Dose | Time | Sample | Description | Target | Raw CS | Normalized CS | −log10q |
|---|---|---|---|---|---|---|---|---|---|
MAP3K9 | AALE | / | 96 h | 3 | / | / | −0.59 | −2.14 | 15.65 |
TGFA | HA1E | 10 ng/ml | 4 h | 3 | / | / | −0.58 | −2.12 | 15.65 |
MAX | SALE | / | 96 h | 3 | / | / | −0.59 | −2.12 | 15.65 |
Reparixin | HT29 | 0.03 μM | 24 h | 2 | CC chemokine receptor antagonist | CXCR1|CXCR2 | −0.58 | −2.1 | 15.65 |
RELB | HT29 | / | 96 h | 3 | / | / | −0.58 | −2.09 | 15.65 |
KIAA0494 | HT29 | 1 μL | 96 h | 3 | / | / | −0.58 | −2.09 | 15.65 |
OTUD7A | HT29 | 1 μL | 96 h | 3 | / | / | −0.58 | −2.09 | 15.65 |
XPO7 | HT29 | / | 96 h | 2 | / | / | −0.57 | −2.08 | 15.65 |
IL1RAP | A375 | / | 96 h | 2 | / | / | −0.57 | −2.07 | 15.65 |
BRD-A47816767 | HT29 | 10 μM | 24 h | 3 | / | / | −0.57 | −2.07 | 15.65 |
BRD-K51126483 | VCAP | 10 μM | 6 h | 4 | / | / | −0.57 | −2.06 | 15.65 |
BRD-K36772364 | HCC515 | 10 μM | 6 h | 3 | / | / | −0.57 | −2.06 | 15.65 |
Formestane | A375 | 10 μM | 6 h | 3 | Selectively steroidal aromatase inhibitor (type I) | / | −0.57 | −2.06 | 15.65 |
BRD-K68657207 | VCAP | 4 μM | 24 h | 3 | / | / | −0.57 | −2.05 | 15.65 |
TCEAL4 | MCF7 | / | 96 h | 2 | / | / | −0.56 | −2.04 | 15.65 |